Randomized Placebo Controlled Trial of Bupropion for Cancer Related Fatigue
安非他酮治疗癌症相关疲劳的随机安慰剂对照试验
基本信息
- 批准号:10394730
- 负责人:
- 金额:$ 59.04万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-06-12 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdherenceAdoptedAffectAftercareAllelesAntidepressive AgentsBehavior TherapyBiologicalBloodBreast Cancer PatientBreast Cancer survivorBupropionCancer CenterCancer PatientClinical TrialsCognitive TherapyCommon Terminology Criteria for Adverse EventsCommunity Clinical Oncology ProgramCytochrome P450CytochromesDataDiseaseDistressDopamine Uptake InhibitorsDouble-Blind MethodExerciseFatigueGenesGeneticGenotypeGoalsHydrocortisoneIncidenceInflammationKnowledgeMalignant NeoplasmsMeasuresMediatingMental DepressionMetabolismModafinilNational Cancer InstituteNorepinephrineParoxetineParticipantPathway interactionsPatient Self-ReportPatientsPharmacotherapyPilot ProjectsPlacebo ControlPlacebosPopulationQuality of lifeRadiation therapyRandomizedRandomized Clinical TrialsRandomized Controlled TrialsReportingResearchResearch PriorityRitalinSalivaSamplingSelective Serotonin Reuptake InhibitorSertralineSleeplessnessSurvivorsSymptomsTNF geneTestingTherapeutic AgentsToxic effectTreatment-Related CancerUniversitiesVariantWomanWorkcancer therapychemotherapydosagedouble-blind placebo controlled trialefficacious treatmentexperiencehypothalamic-pituitary-adrenal axisimprovedmalignant breast neoplasmplacebo groupprogramsrandomized placebo controlled trialrecruit
项目摘要
PROJECT SUMMARY
Fatigue is one of the most prevalent and distressing symptoms experienced by cancer patients. Treatment
options for cancer-related fatigue are limited; additional therapies are a high priority for research. Bupropion
has been identified as a potential therapy for cancer-related fatigue since 1999. Bupropion has diverse actions
that target pathways associated with cancer-related fatigue, including inflammation and hypothalamic pituitary
adrenal (HPA) axis functioning. Metabolism of bupropion by cytochrome P 450 B6 (CYP2B6) has been
extensively characterized. Two pilot studies of bupropion have shown promise in reducing cancer-related
fatigue but to date no adequately-powered, randomized controlled trials have been conducted. The goal of the
current study is to conduct the first adequately-powered, randomized, double-blinded, placebo-controlled trial
of bupropion for cancer-related fatigue. Because fatigue is well-characterized in women with breast cancer,
the study will focus on this population. A sample of 422 disease-free breast cancer patients who completed
chemotherapy and/or radiotherapy 12-60 months previously and report significant fatigue will be recruited
through the University of Rochester Cancer Center (URCC) National Cancer Institute Community Oncology
Research Program (NCORP). Participants will be randomized 1:1 to receive generic bupropion XL or placebo.
Fatigue will be assessed prior to randomization and 12 weeks later. Blood and saliva will be collected to
measure bupropion metabolites, inflammation, CYP2B6 genotype, and cortisol (a marker for HPA axis
functioning). Data will be used to address the following aims: 1) to determine the efficacy of bupropion versus
placebo in reducing fatigue in a double-blinded, placebo-controlled, randomized clinical trial of breast cancer
survivors with fatigue; 2) to assess the tolerability of bupropion in breast cancer survivors with fatigue, 3) to
explore the effects of bupropion on putative mechanisms of cancer-related fatigue, and 4) to explore
associations of CYP2B6 genotype with bupropion metabolism and changes in fatigue. Positive results from
the current study could revolutionize the treatment of cancer-related fatigue, as bupropion is safe, inexpensive,
widely-available, and may be more tolerable and acceptable for many patients than current, limited treatment
options. Exploration of the effects of bupropion on putative mechanisms of cancer-related fatigue could open
new avenues for additional efficacious treatments. Exploration of genetic moderators of efficacy could help
identify which patients are most likely to benefit and tailor dosage.
项目总结
疲劳是癌症患者最普遍和最痛苦的症状之一。治疗
治疗癌症相关性疲劳的选择有限;其他治疗方法是研究的高度优先事项。安非他酮
自1999年以来一直被确定为治疗癌症相关疲劳的一种潜在疗法。安非他酮有多种作用
靶向与癌症相关的疲劳的通路,包括炎症和下丘脑脑垂体炎
肾上腺(HPA)轴功能。细胞色素P450 B6对安非他酮的代谢
具有广泛的特征。安非他酮的两项初步研究显示,它有望减少与癌症相关的疾病
疲劳,但到目前为止还没有进行动力充足的随机对照试验。的目标是
目前的研究是进行第一个充分有效、随机、双盲、安慰剂对照的试验
用于治疗癌症相关疲劳的安非他酮。因为疲倦是乳腺癌女性的显著特征,
这项研究将重点放在这一人群上。完成调查的422名无病乳腺癌患者样本
化疗和/或放射治疗前12-60个月,并报告严重疲劳将被招募
通过罗切斯特大学癌症中心(URCC)国家癌症研究所社区肿瘤学
研究计划(NCORP)。参与者将以1:1的随机比例接受非专利安非他酮XL或安慰剂治疗。
疲劳将在随机化之前和12周后进行评估。血液和唾液将被收集到
测量安非他酮代谢物、炎症、CYP2B6基因和皮质醇(HPA轴的标记物
功能)。数据将被用来解决以下目标:1)确定安非他酮与
安慰剂在乳腺癌双盲、安慰剂对照、随机临床试验中减轻疲劳的作用
疲劳症幸存者;2)评估乳腺癌疲劳症幸存者对安非他酮的耐受性;3)
探索安非他酮对癌症相关性疲劳的可能机制的影响,以及4)探索
CYP2B6基因与安非他酮代谢和疲劳改变的关系。积极的结果来自
目前的研究可能会给癌症相关性疲劳的治疗带来革命性的变化,因为安非他酮是安全、廉价的,
可广泛获得,而且可能比目前的有限治疗更容易被许多患者耐受和接受
选择。探讨安非他酮对癌症相关性疲劳的可能机制的影响
寻找其他有效治疗方法的新途径。探索疗效的遗传调节因素可能会有所帮助
确定哪些患者最有可能受益,并量身定制剂量。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HEATHER S.L. JIM其他文献
HEATHER S.L. JIM的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HEATHER S.L. JIM', 18)}}的其他基金
Neurocognitive and Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell Therapy: A Controlled Comparison
嵌合抗原受体 T 细胞治疗后的神经认知和患者报告结果:对照比较
- 批准号:
10444276 - 财政年份:2022
- 资助金额:
$ 59.04万 - 项目类别:
Neurocognitive and Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell Therapy: A Controlled Comparison
嵌合抗原受体 T 细胞治疗后的神经认知和患者报告结果:对照比较
- 批准号:
10656253 - 财政年份:2022
- 资助金额:
$ 59.04万 - 项目类别:
Accelerated aging after chimeric antigen receptor T-cell therapy (CART): Leveraging a novel population of cancer survivors to elucidate mechanisms of dementia
嵌合抗原受体 T 细胞疗法 (CART) 后加速衰老:利用新型癌症幸存者群体来阐明痴呆机制
- 批准号:
10719874 - 财政年份:2022
- 资助金额:
$ 59.04万 - 项目类别:
Randomized Placebo Controlled Trial of Bupropion for Cancer Related Fatigue
安非他酮治疗癌症相关疲劳的随机安慰剂对照试验
- 批准号:
10166792 - 财政年份:2018
- 资助金额:
$ 59.04万 - 项目类别:
Improving Prediction of Chemotherapy-Induced Nausea: Integrating Genes, Behavior, and the Microbiome
改善化疗引起恶心的预测:整合基因、行为和微生物组
- 批准号:
10166795 - 财政年份:2018
- 资助金额:
$ 59.04万 - 项目类别:
Improving Prediction of Chemotherapy-Induced Nausea: Integrating Genes, Behavior, and the Microbiome
改善化疗引起恶心的预测:整合基因、行为和微生物组
- 批准号:
10442417 - 财政年份:2018
- 资助金额:
$ 59.04万 - 项目类别:
Internet-Assisted Cognitive Behavior Intervention for Targeted Therapy Fatigue
互联网辅助认知行为干预靶向治疗疲劳
- 批准号:
8990831 - 财政年份:2015
- 资助金额:
$ 59.04万 - 项目类别:
Sickness Behaviors in Gynecologic Cancer Patients Treated with Chemotherapy
接受化疗的妇科癌症患者的疾病行为
- 批准号:
9093714 - 财政年份:2012
- 资助金额:
$ 59.04万 - 项目类别:
Sickness Behaviors in Gynecologic Cancer Patients Treated with Chemotherapy
接受化疗的妇科癌症患者的疾病行为
- 批准号:
8515362 - 财政年份:2012
- 资助金额:
$ 59.04万 - 项目类别:
Sickness Behaviors in Gynecologic Cancer Patients Treated with Chemotherapy
接受化疗的妇科癌症患者的疾病行为
- 批准号:
8687616 - 财政年份:2012
- 资助金额:
$ 59.04万 - 项目类别:
相似海外基金
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
- 批准号:
2325465 - 财政年份:2023
- 资助金额:
$ 59.04万 - 项目类别:
Standard Grant
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
- 批准号:
490105 - 财政年份:2023
- 资助金额:
$ 59.04万 - 项目类别:
Operating Grants
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
- 批准号:
10057526 - 财政年份:2023
- 资助金额:
$ 59.04万 - 项目类别:
Grant for R&D
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
- 批准号:
10772887 - 财政年份:2023
- 资助金额:
$ 59.04万 - 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
- 批准号:
10766947 - 财政年份:2023
- 资助金额:
$ 59.04万 - 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 59.04万 - 项目类别:
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
- 批准号:
10821172 - 财政年份:2023
- 资助金额:
$ 59.04万 - 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
- 批准号:
10748465 - 财政年份:2023
- 资助金额:
$ 59.04万 - 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
- 批准号:
10591441 - 财政年份:2023
- 资助金额:
$ 59.04万 - 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
- 批准号:
491109 - 财政年份:2023
- 资助金额:
$ 59.04万 - 项目类别:
Fellowship Programs